Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 2, 2000, Pages 85-92

  Mehta, Shashi ^a   Blackinton, Dilshad ^a   Omar, Imran ^a   Kouttab, Nicola ^a   Myrick, Dorkina ^a   Klostergaard, Jim ^b   Wanebo, Harold ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ceramide; Paclitaxel; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDE; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 0033897314     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000140     Document Type: Article

References (51)

1. Antineoplastic activity of taxol against human neoplastic thyroid carcinoma cell lines in vitro and in vivo
2. 2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts
3. Selective involvement of caspase-3 in ceramide induced apoptosis in AK-5 tumor cells
4. Modulation of cell growth and differentiation by ceramide
5. Ceramide synthase mediates daunorubicin-induced apoptosis and alternative mechanism for generating death signals
6. The biochemistry of cell death by apoptosis
7. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing
8. Quantitative analysis of dose-effect relationships: The combined effect of multiple drugs and enzyme inhibitors
9. Alterations of lymphocyte microtubule assembly, cytotoxicity and activation by the anticancer drug Taxol
10. Gene therapy for head and neck cancer
11. A pilot trial of paclitaxel, carboplatin and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck
12. Paclitaxel in head and neck cancer and other tumor types
13. Phase 1 study of paclitaxel and carboplatin: Implications for trials in head and neck cancer
14. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
15. Antagonists of nucleic acid derivatives. VIII: Synergism in combinations of biochemically related antimetabolites
16. Squamous cell carcinoma is highly Sensitive to taxol, a possible new radiation sensitizer
17. Paclitaxel (Taxol) for the treatment of head and neck cancer
18. Simple agents paclitaxel and paclitaxel tifosfamide in the treatment of head and neck cancer
19. Paclitaxel and carboplatin in recurrent and metastatic head and neck cancer: A phase II study
20. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
21. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells
22. The sphingomyelin cycle and the second messenger function of ceramide
23. Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer
24. Phase 11 trial of Taxol, an active drug in the treatment of metastatic breast cancer
25. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway
26. Role for ceramide in cell cycle arrest
27. Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics
28. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling
29. Paclitaxel enhances in vitro radiosensitivity of squamous cell carcinoma of the head and neck
30. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells
31. Growth suppression of head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus
32. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
33. Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide
34. Ceramide: A stress signal and mediator of growth suppression and apoptosis
35. Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer
36. Taxol plus radiation for head and neck cancer
37. Paclitaxel
38. Microtubule change and cytotoxicity in leukemia cell lines treated with Taxol
39. Taxol stabilizes microtubules in mouse fibroblast cells
40. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor saffingol alone and in combination with doxorubicin
41. Phase I trial of adriamycin + Taxol in metastatic breast cancer
42. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck cancer: Correlative lab studies
43. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase
44. Taxol sensitizes human ovarian cancer cells to radiation
45. 1-β-D arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells
46. Sphingosine and its methylated derivative N,N-dimethyl sphingosine (DMS) induce apoptosis in a variety of human cancer cell lines
47. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
48. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
49. Preoperative paclitaxel, carboplatin and radiation in advanced head and neck cancer (Stage III and IV) induces high rate of complete pathologic response (CR) at the primary site and high rate of organ preservation
50. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways
51. Ceramide activates the stress-activated protein kinases